Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Apo-Topiramate · DIN 02279630 Manufacturer: Apotex Inc.; listing date 2006-06-14 Health Canada: Marketed since 2006-04-21 · brand APO-TOPIRAMATE · ATC N03AX11 TOPIRAMATE · form Tablet · route Oral · ingredients TOPIRAMATE 100 MG · company Apotex inc · schedule Prescription

DIN 02279630: Apo-Topiramate Raw flags: sec3=Y Item: 281200070; group id 446; item number 1117; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.4583; ministry $0.4583 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02279630 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76524

Interchangeable products

AG-Topiramate · DIN 02475944 · $0.4583 Ach-Topiramate · DIN 02395746 · $0.4583 Auro-Topiramate · DIN 02345838 · $0.4583 Jamp Topiramate Tablets · DIN 02345269 · $0.4583 Jamp-Topiramate · DIN 02435616 · $0.4583 Mar-Topiramate · DIN 02432102 · $0.4583 Mint-Topiramate · DIN 02315653 · $0.4583 Mylan-Topiramate · DIN 02263378 · $0.4583 NRA-Topiramate · DIN 02538458 · $0.4583 PMS-Topiramate · DIN 02263009 · $0.4583 Ran-Topiramate · DIN 02396084 · $0.4583 Sandoz Topiramate Tablets · DIN 02431815 · $0.4583 Teva-Topiramate · DIN 02248861 · $0.4583 Topamax · DIN 02230894 · $0.4583 Topiramate · DIN 02356864 · $0.4583 Topiramate · DIN 02389487 · $0.4583

Shortage status: not checked (no credentials)